Doxorubicin liposomal - Perrigo

Drug Profile

Doxorubicin liposomal - Perrigo

Alternative Names: Myocet; NSC 620212; TLC D99; TLC Dox99

Latest Information Update: 30 Nov 2016

Price : $50

At a glance

  • Originator Elan Corporation
  • Developer Sopherion Therapeutics; Zeneus Pharma
  • Class Anthracyclines; Cytostatic antibiotics; Doxorubicins; Small molecules
  • Mechanism of Action Reactive oxygen species stimulants; RNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer

Most Recent Events

  • 28 Sep 2016 Efficacy and adverse events data from a phase II trial in Breast cancer presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
  • 15 Mar 2016 Biomarkers information updated
  • 01 Dec 2015 Cephalon completes a phase II trial in Breast cancer (Metastatic disease, First-line therapy, Combination therapy) in United Kingdom, Netherland, Austria, Belgium, France, Germany, Italy and Spain (NCT00712881)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top